What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 2
- “The goal of this clinical trial is to learn about the safety of the investigational medicinal product ANXV. It will also learn about how ANXV works to treat non-proliferative diabetic retinopathy and retinal vein occlusion in adults. The main questions it aims to answer are: * Is ANXV safe to use? * Does ANXV improve vision or findings related to vision decrease caused by non-proliferative diabetic retinopathy or retinal vein occlusion? * Does ANXV lower the number of times participants need to use a rescue medication? Researchers will compare different dose levels of ANXV to see what dose…”In the company’s words, NCT07259928 on ClinicalTrials.gov
Other drugs for Non-Proliferative Diabetic Retinopathy
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Jul 2026 | Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion | |
| Phase 2Completed | 17 Jul 2024 | Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion | |
| Phase 1Completed | 27 Oct 2021 | First in Human Study of ANXV (Recombinant Human Annexin A5) in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026